Insulin manufacturers, PBMs spar over rebates and pricing

Insulin manufacturers and PBMs sparred at a congressional hearing Wednesday, blaming each other for escalating list prices of diabetes drugs and offering opposing policy prescriptions.

The three companies that manufacture almost all of the insulin sold in the U.S., Eli Lilly and Co. (NYSE:LLY), Sanofi (Euronext:SAN; NASDAQ:SNY) and Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO), highlighted their discount and patient assistance programs.

Sanofi announced an expansion

Read the full 638 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE